Related Experiment Video
Updated: Jun 27, 2025
Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting
Published on: March 25, 2019
Targeting tumour markers in ovarian cancer treatment
Subham Preetam1, Sagar Mondal2, Swati Priya2
1Department of Robotics and Mechatronics Engineering, Daegu Gyeongbuk Institute of Science & Technology (DGIST) Dalseong-gun, Daegu 42988, South Korea.
Abstract:
Ovarian cancers (OC) are the most common, lethal, and stage-dependent cancers at the global level, specifically in female patients. Targeted therapies involve the administration of drugs that specifically target the alterations in tumour cells responsible for their growth, proliferation, and metastasis, with the aim of treating particular patients. Presently, within the realm of gynaecological malignancies, specifically in breast and OCs, there exist various prospective therapeutic targets encompassing tumour-intrinsic signalling pathways, angiogenesis, homologous-recombination deficit, hormone receptors, and immunologic components. Breast cancers are often detected in advanced stages, primarily due to the lack of a reliable screening method. However, various tumour markers have been extensively researched and employed to evaluate the condition, progression, and effectiveness of medication treatments for this ailment. The emergence of recent technological advancements in the domains of bioinformatics, genomics, proteomics, and metabolomics has facilitated the exploration and identification of hitherto unknown biomarkers. The primary objective of this comprehensive review is to meticulously investigate and analyze both established and emerging methodologies employed in the identification of tumour markers associated with OC.
Insights
This review explores established and emerging methods for identifying ovarian cancer (OC) tumor markers. Advances in bioinformatics and genomics aid in discovering novel biomarkers for targeted therapies.
Area of Science:
- Oncology
- Biomarker Discovery
- Genomics
Background:
- Ovarian cancer (OC) is a leading cause of cancer death in women, often diagnosed at advanced stages.
- Targeted therapies aim to treat specific patient populations by targeting tumor cell alterations.
- Reliable screening methods for OC are lacking, highlighting the importance of tumor markers.
Purpose of the Study:
- To review established and emerging methodologies for identifying tumor markers in ovarian cancer.
- To analyze the role of technological advancements in biomarker discovery for OC.
- To provide a comprehensive overview of current and future approaches in OC marker identification.
Main Methods:
- Literature review of established and emerging tumor marker identification methodologies.
- Analysis of advancements in bioinformatics, genomics, proteomics, and metabolomics.
- Synthesis of information on therapeutic targets in gynecological malignancies, including OC.
Main Results:
- Tumor markers are crucial for evaluating OC condition, progression, and treatment efficacy.
- Bioinformatics, genomics, proteomics, and metabolomics are driving the discovery of novel OC biomarkers.
- Established and emerging methods are continuously refining OC diagnosis and treatment strategies.
Conclusions:
- Accurate identification of OC tumor markers is essential for effective targeted therapy.
- Technological advancements are significantly enhancing the discovery of novel biomarkers for ovarian cancer.
- Continued research into tumor markers will improve patient outcomes and treatment strategies for OC.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy